A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer

医学 化疗 内科学 肺癌 进行性疾病 肿瘤科 不利影响 胃肠病学 外科
作者
Haiying Wang,Junfeng Chu,Yan Zhao,Hong Tang,Lili Wang,Meng-qiang Zhou,Zheng Yan,Yanyan Liu,Zhihua Yao
出处
期刊:Cancer management and research [Dove Medical Press]
卷期号:Volume 12: 3827-3834 被引量:21
标识
DOI:10.2147/cmar.s249678
摘要

PURPOSE: Anlotinib is a newly developed oral multitarget tyrosine kinase inhibitor. We retrospectively evaluated the toxicity and clinical efficacy of chemotherapy combined with anlotinib versus chemotherapy alone for metastatic/advanced non-small cell lung cancer (NSCLC) in patients who failed first- or second-line systemic treatment in China. PATIENTS AND METHODS: In this retrospective trial, ninety-four advanced NSCLC patients received chemotherapy combined with anlotinib (n = 41) or chemotherapy alone (n = 53) in Henan Cancer Hospital. We recorded the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and adverse events (AEs). RESULTS: In the anlotinib plus chemotherapy group, eleven patients (27%) achieved a PR (partial response), and twenty-one patients (51%) achieved SD (stable disease), with an ORR of 27% and a DCR of 78%. In the chemotherapy alone group, eight patients (15%) achieved a PR, and nineteen patients (36%) had SD, with an ORR of 15% and a DCR of 51%. The ORR in the combination arm was slightly, but not obviously, higher than that in the chemotherapy arm (27% vs 15%, p > 0.05). In addition, the DCR was significantly higher in the combination arm than in the chemotherapy alone arm (78% vs 51%, p=0.007). At the end of follow-up, patients in the combination arm had a 1.5-month longer median PFS than patients in the chemotherapy arm; this difference was statistically significant (5.0 vs 3.5, p=0.002). The median OS was not achieved at the final analysis. The hematological and nonhematological toxicities were well tolerated and controlled. In general, most toxicity was limited to grade I or II, well tolerated and controlled. CONCLUSION: Our study suggests that anlotinib combined with chemotherapy may be an effective and well-tolerated treatment for advanced NSCLC in patients who fail first- or second-line therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello的应助被谨慎雪碧采纳,获得10
刚刚
搜集达人的应助被wyr采纳,获得10
刚刚
刚刚
大模型的应助被e00ec采纳,获得10
刚刚
科研蚂蚁发布了新的文献求助10
1秒前
AA发布了新的文献求助10
2秒前
itsuka完成签到,获得积分10
3秒前
浮云发布了新的文献求助10
4秒前
Elsevier大王的应助被twive采纳,获得30
6秒前
xiaobin完成签到 ,获得积分10
6秒前
ahhh完成签到,获得积分10
6秒前
6秒前
jht456完成签到,获得积分10
7秒前
虚心向上完成签到 ,获得积分10
7秒前
华仔的应助被KIKI采纳,获得10
7秒前
橙花完成签到,获得积分10
7秒前
8秒前
8秒前
10秒前
周末完成签到,获得积分10
10秒前
11秒前
orixero的应助被科研通管家采纳,获得10
12秒前
Jasper的应助被科研通管家采纳,获得10
12秒前
daomaihu发布了新的文献求助100
12秒前
乐空思的应助被科研通管家采纳,获得30
12秒前
无极微光的应助被科研通管家采纳,获得20
12秒前
汉堡包的应助被科研通管家采纳,获得10
12秒前
12秒前
科目三的应助被科研通管家采纳,获得10
12秒前
13秒前
脑洞疼的应助被科研通管家采纳,获得10
13秒前
深情安青的应助被科研通管家采纳,获得10
13秒前
科研小白给科研小白的求助进行了留言
13秒前
李爱国的应助被科研通管家采纳,获得10
13秒前
13秒前
zq123完成签到,获得积分10
13秒前
13秒前
斯文败类的应助被科研蚂蚁采纳,获得10
13秒前
wanci的应助被科研通管家采纳,获得10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175267
求助须知:如何正确求助?哪些是违规求助? 9567035
关于积分的说明 21789830
捐赠科研通 7769741
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556149
邀请新用户注册赠送积分活动 2477241